Search Results
Nov 24, 2025, 07:00 ET Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
9 registrational clinical studies in China. MSD has initiated 15 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.About Kelun-BiotechKelun-Biotech
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 19, 2025, 13:05 ET Rutgers Business School's Road to Wall Street Program allows first-generation student to chart his future in finance
a gift from Rutgers Business School alumnus Robert Platek and MSD Partners. His internships in finance confirmed Morales was on the right path. The summer after sophomore year, he worked at
More news about: Rutgers Business School
Nov 17, 2025, 13:00 ET Now Open: Naples Beach Club, A Four Seasons Resort, Welcomes Guests To A New Era of Coastal Luxury In Southwest Florida
unparalleled level of refinement and elegance. This landmark addition to the Four Seasons portfolio was brought to life through the shared vision of BDT & MSD, The Athens Group, and Four Seasons.
More news about: Four Seasons Hotels and Resorts
Nov 10, 2025, 11:00 ET Pesquisa inédita revela que 64% dos homens desconhecem a relação entre HPV e câncer
Link Sobre a MSD Por mais de 130 anos, a MSD cria invenções para a vida, trazendo ao mercado medicamentos inovadores para combater as doenças mais desafiadoras. MSD é o nome pelo qual é conhecida a Merck & Co. Inc. fora dos Estados
More news about: MSD
Nov 09, 2025, 20:55 ET Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
9 registrational clinical studies in China. MSD has initiated 15 ongoing Phase Ⅲ global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 06, 2025, 15:41 ET South Street Partners and Dream Finders Homes Acquire Sawgrass Marriott Golf Resort & Spa in Ponte Vedra Beach, Florida
since 1982, and just minutes from the newly delivered PGA TOUR Global Home and PGA TOUR Studios. The acquisition financing was provided by BDT & MSD Partners' affiliated funds.
More news about: South Street Partners
Nov 06, 2025, 09:00 ET Metropolis Secures $1.6B in Financing From Leading Global Investors
The Series D values Metropolis at approximately $5B and saw participation from BDT & MSD Partners' affiliated credit funds, DFJ, Eldridge Industries, Slow Ventures, SoftBank Vision Fund 2, Tekne Capital, and Vista. The financing positions
More news about: Metropolis
Nov 03, 2025, 08:08 ET Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, plus pembrolizumab (KEYTRUDA®), Merck's (known as MSD outside of the United States and Canada) anti-PD-1 therapy, versus treatment of physician's choice for patients with advanced endometrial carcinoma following
More news about: Eisai Inc.
Oct 28, 2025, 06:05 ET Carrier Reports Third Quarter 2025 Results
exit Organic* up MSD FX 1%
More news about: Carrier Global Corporation
Oct 23, 2025, 11:55 ET eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating Shiftconnector
More news about: eschbach
Oct 23, 2025, 07:00 ET Medison Strengthens its Global Commercialization Platform, Appoints Francis Wan as VP, GM Asia Pacific
of biopharmaceutical leadership experience, including serving as President Asia Pacific at Biogen and Managing Director of Commercial Operations at MSD China, he has successfully scaled organizations, advanced innovative therapies, and built sustainable access models across diverse APAC markets. His
More news about: Medison Pharma
Oct 23, 2025, 07:00 ET Medison Strengthens its Global Commercialization Platform, Appoints Francis Wan as VP, GM Asia Pacific
of biopharmaceutical leadership experience, including serving as President Asia Pacific at Biogen and Managing Director of Commercial Operations at MSD China, he has successfully scaled organizations, advanced innovative therapies, and built sustainable access models across diverse APAC markets. His
More news about: Medison Pharma
Oct 23, 2025, 07:00 ET Medison Strengthens its Global Commercialization Platform, Appoints Francis Wan as VP, GM Asia Pacific
of biopharmaceutical leadership experience, including serving as President Asia Pacific at Biogen and Managing Director of Commercial Operations at MSD China, he has successfully scaled organizations, advanced innovative therapies, and built sustainable access models across diverse APAC markets. His
More news about: Medison Pharma
Oct 22, 2025, 08:51 ET RoundTable Healthcare Partners Completes Sale of Stake in Designs for Health Following a Successful Partnership
RoundTable concludes its investment after a collaborative multi-year partnership with the Lizotte family, as DFH welcomes BDT & MSD Partners to support its continued growth LAKE FOREST, Ill.,
More news about: RoundTable Healthcare Partners
Oct 21, 2025, 19:30 ET PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
December 14, 2023. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada). Cautionary Notes In this press
More news about: Astellas Pharma Inc.
Oct 21, 2025, 09:00 ET Designs for Health Announces Strategic Investment from BDT & MSD Partners to Support Continued Growth and Innovation
https://www.designsforhealth.com/our-story About BDT & MSD Partners BDT & MSD Partners is a merchant bank with an advisory and investment platform built to serve the distinct needs of business owners
More news about: Designs for Health
Oct 20, 2025, 04:57 ET The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
registrational clinical studies in China. MSD has initiated 15 ongoing Phase Ⅲ global clinical studies of sac-TMT as a monotherapy or with pembrolizumab1 or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 19, 2025, 22:01 ET Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
9 registrational clinical studies in China. MSD has initiated 15 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 18, 2025, 10:42 ET Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
9 registrational clinical studies in China. MSD has initiated 15 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Oct 18, 2025, 10:30 ET PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
December 14, 2023. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada). Astellas Cautionary Notes In
More news about: Astellas Pharma Inc.
Oct 16, 2025, 11:00 ET The CIO Group Releases Outlook 2026: "Unprecedented Times, Exceptional Portfolios"
2025 /PRNewswire/ -- The CIO Group ("CIOG"), a new wealth intelligence firm founded by David Bailin and leaders from Citi, JPMorgan, BDT & MSD, and top family offices, today released its Outlook 2026, "Unprecedented Times, Exceptional Portfolios." Authored by CIOG Chief Investment Strategist
More news about: CIO Group
Oct 14, 2025, 08:34 ET Debbie's Dream Foundation and Partners to Host International Gastric Cancer Educational Symposium in Tokyo
AstraZeneca, and Bristol Myers Squibb. Additional support is provided by Kibounoukai Sponsors, Boehringer Ingelheim, Daiichi-Sankyo, Pfizer, Roche, MSD, and Chugai. To learn more and register, visit
More news about: Debbie's Dream Foundation: Curing Stomach Cancer
Oct 10, 2025, 16:15 ET Alliance Laundry Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BofA Securities and J.P. Morgan acted as joint lead book-running managers. Morgan Stanley acted as book-running manager. Baird, BDT & MSD Partners, BMO Capital Markets, Citigroup, Goldman Sachs & Co. LLC and UBS Investment Bank acted as additional bookrunners. CIBC Capital Markets,
More news about: Alliance Laundry Systems
Oct 09, 2025, 18:27 ET Biopharma-Führungskräfte bringen die Zukunft der Biowissenschaften auf dem Veeva Commercial Summit Europe voran
trifft sich, um die KI-Innovationen von Veeva zu erkunden und Ideen mit Unternehmen wie Astellas, Bayer AG, Boehringer Ingelheim, LEO Pharma, Moderna und MSD auszutauschen BARCELONA, Spanien, 10.
More news about: Veeva Systems
Oct 09, 2025, 17:31 ET Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight
Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, among others.
More news about: DelveInsight Business Research, LLP